0.97
-2.88%
Close of 5 Nov 2026, in USD
About ABVC Biopharma
From its filings with the US Securities and Exchange Commission
ABVC Biopharma is based in Fremont, California and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker ABVC. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2024, it reported revenue of $509,589.
ABV-1504, Major Depressive Disorder (MDD), Phase II completed. NCE drug Principal Investigators: Charles DeBattista M.D. and Alan F.
Duangnate Rojanaporn, M.D., Ramathibodi Hospital; Thuss Sanguansak, M.D., Srinagarind Hospital of the two Thailand Sites and Professor/Dr.
ABVC plans to recruit a maximum number of 54 cancer patients with depression, to whom ABVC intends to administer ABV-1601 oral capsules.
States diagnosed with either IPSS int-1, IPSS int-2 high-risk MDS, or CMML and may take azacitidine as part of the subjects’ prescription.
Azacitidine is an FDA-approved drug used to treat MDS. ABVC intends to administer ABV-1702 in the oral liquid form along with azacitidine.
ABV- 1501 is developed from BLI-1401-2, whose active pharmaceutical ingredient is Yukiguni Maitake Extract 404. Memorial Sloan Kettering Cancer Center (“MSKCC”) conducted the Phase I clinical trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom), which is very similar to Yukiguni Maitake Extract 404. The Phase I trial focused on the immunological effects of Grifola frondosa extract on breast cancer patients. The results of the Phase I trial showed that oral administration of a polysaccharide extract from Maitake mushroom is associated with both immunologically stimulatory and inhibitory measurable effects in peripheral blood.
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 9 Nov 2004
- Employees
- 30
- Head office
- 44370 OLD WARM SPRINGS BLVD., FREMONT, CA, 94538
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Eugene JiangChairman of the Board, Chief Business Officer, since 2015$415,244
- Dr. Uttam PatilChief Executive Officer, Interim Chief Financial Officer$107,623
- Dr. Tsung-Shann JiangChief Scientific Officer, Chief Strategy Officer, Director, since 2018$353,746
- Dr. Chang-Jen JiangDirector
- Ms. Shuling JiangDirector
- Dr. Tsang Ming JiangDirector
- Ms. Yen-Hsin ChouIndependent Director
- Mr. Yu- Min ChungIndependent Director
- Ms. Che-Wei HsuIndependent Director
- Ms. Hsin-Hui MiaoIndependent Director
- Mr. Yoshinobu OdairaIndependent Director
- Ms. Norimi SakamotoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ABVC Biopharma Inc. develops five licensed compounds including ABV-1501 for cancer treatment.
- The company focuses on enhancing pre-existing pharmaceutical products for various cancer indications.
- ABVC Biopharma Inc. utilizes licensed technology to identify responsive patients for pharmaceutical products.
Weaknesses
- The company had no revenue as of September 30, 2016, indicating early-stage financial challenges.
- ABVC Biopharma Inc. employs only 30 full-time employees, limiting operational capacity.
- The firm's clinical-stage development requires significant investment without current revenue streams.
Opportunities
- ABVC Biopharma Inc. can commercialize licensed pharmaceutical products in various global markets.
- The company's compounds ABV-1501 to ABV-1505 offer potential for expanding cancer treatment options.
- Licensing agreements with BioLite Inc. provide a foundation for future drug development.
Threats
- The clinical-stage biopharmaceutical company faces high development costs without revenue generation.
- ABVC Biopharma Inc. must secure additional funding to advance its five compound development.
- Competition in the cancer treatment market may impact the commercialization of ABV-1501 to ABV-1505.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.